Numerous studies have demonstrated that KRAS inhibition reverses immune suppression, causes a profound remodelling of the tumour immune microenvironment (TME) and activates anti-tumour immunity, which provides a window of opportunity for combination with immunotherapies24–26. The gene discussed is KRAS; the disease is neoplasm.